Ultime notizie per Bloom Energy (NYSE:BE) Azioni

Bloom Energy

Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and South Korea.

Bloom Energy Corporation Class A Common Stock

Bloom Energy Corp

Bold Eagle Acquisition Corp

Beam Therapeutics Inc

BEAM - United States Dollar

BEAR Coin - United States Dollar

HeartBeam Inc

bebe stores Inc

BCE Inc

Beacon Roofing Supply, Inc. - Common Stock

Beacon Roofing Supply Inc

BlackRock ETF Trust Future Climate & Sustainable Economy ETF

Bechtle AG

BEC WRLD PCL ADR by Bec World Public Co., Ltd.

BEC World PCL

Bright Scholar Education Holdings Limited American Depositary Shares, each representing four Class A Ordinary Share

Bright Scholar Education Holdings Ltd

BRIGHT SCHLR EDCN ADR REP 4 CL A ORD

AdvisorShares Hotel ETF

BALD EAGLE ENERGY INC by Bald Eagle Energy, Inc.

Beam Global

BETTER ENVIRONMENT CNCPT by Better Environment Concepts, Inc.

Mobile Infrastructure Corporation Common Stock

Mobile Infrastructure Corp

Honeytree U.S. Equity ETF

BLACKSTAR ENTERPRISE GRP by BlackStar Enterprise Group, Inc.

Blackstar Enterprise Group Inc

BIOCENTRIC ENGY HLDGS INC by Biocentric Energy Holdings, Inc.

Biocentric Energy Holdings

BeiGene Ltd

BEIJING NORTH STAR CORP by Beijing North Star Corp.

Beijing North Star Co Ltd

NV Bekaert SA

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

KE Holdings Inc

KE HOLDINGS ADR REP 3 CL A ORD

Bella Protocol

Batero Gold Corp

Bel Fuse Inc

Bellevue Gold Ltd

BELMONT RESOURCES INC by Belmont Resources, Inc.

Belmont Resources Inc

BELL ROSE CAPITAL INC by Bell Rose Capital Inc.

Bell Rose Capital Inc

iShares Long-Term U.S. Equity Active ETF

Belt Finance

BEMIL Coin

iShares Trust iShares J.P. Morgan Broad USD Emerging Markets Bond ETF

Franklin Resources Inc

BENS CREEK GROUP PLC by BENS CREEK GROUP PLC

Bens Creek Group PLC

Beneficient

BARITO RENEWABLES ENERGY by BARITO RENEWABLES ENERGY TBK

BIO-EN HOLDINGS CORP by Bio-En Holdings Corp.

Bio-En Holdings Corp

Benz Mining Corp

BEO Bancorp OR

Beyond Oil Ltd

Brookfield Renewable Partners LP

Brookfield Renewable Corporation Class A Subordinate Voting Shares

Brookfield Renewable Corp

Brookfield BRP Holdings (Canada) Inc. 4.625% Perpetual Subordinated Notes

Brookfield BRP Holdings (Canada) Inc. 4.875% Perpetual Subordinated Notes

Brookfield BRP Holdings (Canada) Inc. 7.250% Perpetual Subordinated Notes

BROMPTON FLAHTY AND CRM ENH GRD ETF

BEPRO Network

Beach Energy Ltd

Brookfield Renewable Partners L.P. 5.25% Class A Preferred Limited Partnership Units, Series 17

BLUE EARTH RES INC by Blue Earth Resources, Inc.

Blue Earth Resources Inc

Berry Global Group Inc

MicroSectors FANG & Innovation -3x Inverse Leveraged ETN

Besra Gold Inc

BELSHIPS CO LTD ORD by Belships Co., Ltd.

Belships ASA

BE SMCNDCTR INDUS S/ADR by BE Semiconductor Industries N.V.

BE Semiconductor Industries NV

BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

BEST Inc

Bitpanda - United States Dollar

BE SMCNDCTR INDUS N V by BE Semiconductor Industries N.V.

BE SEMICONDUCT ORD

Beta Finance

ProShares Bitcoin & Ether Equal Weight ETF

ProShares Bitcoin & Ether Market Cap Weight ETF

Better Home & Finance Holding Company - Class A Common Stock

Better Home & Finance Holding Co

BETTERLIFE PHARMA INC by BETTERLIFE PHARMA INC.

BetterLife Pharma Inc

Better Home & Finance Holding Company - Warrant

BIT BROTHER LIMITED A by Bit Brother Limited

Bit Brother Ltd

BetU

BETTWORK INDUSTRIES INC by Bettwork Industries Inc.

Bettwork Industries Inc

Roundhill Sports Betting & iGaming ETF

SCIENCE TO CONSUMERS INC by Science to Consumers, Inc.

Science to Consumers Inc

Winc, Inc

DIVERSIFIED ROYALTY CORP by Diversified Royalty Corp.

Diversified Royalty Corp

BEE VECTORING TECH ORD by Bee Vectoring Technologies International Inc.

Bee Vectoring Technologies International Inc

BEWHERE HLDGS INC by BeWhere Holdings Inc.

BeWhere Holdings Inc

<a href="https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/01/statement-from-president-joe-biden-on-the-october-2024-jobs-report/" title="https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/01/statement-from-president-joe-biden-on-the-october-2024-jobs-report/">https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/01/statement-from-president-joe-biden-on-the-october-2024-jobs-report/</a>

Macro Notification

News

General

Biden, Responding To October Jobs Data, Says Job Growth Is Expected To Rebound In November; Adds ' There's More Work To Do'; Says Hurricanes, Strike Activity Lowered Job Growth

On Thursday, ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) announced its plans to terminate the Phase 2 trial of masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer (mCRPC) naïve to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41669391/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined-with-enzalutami" rel="noreferrer noopener">second-generation antiandrogens</a>.
This decision was based on a protocol-specified interim review of the safety, PK, and efficacy data, which showed a much higher rate of PSA90 response in patients treated with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xtandi (enzalutamide) monotherapy (which is the standard of care for this patient population) than expected based on historical data.
In addition, there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.
A futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study.
The combination of masofaniten plus enzalutamide was well-tolerated with no new safety signals and a safety profile similar to that seen in Phase 1 studies.
&#8220;We made the difficult decision to terminate this Phase 2 study following the interim analysis because we concluded that the emerging efficacy profile of masofaniten combined with enzalutamide would not likely meet the primary endpoint of the study, nor our internal requirements for a prostate cancer therapy candidate,&#8221; said&nbsp;David Parkinson, President, and CEO.
As part of the effort to focus its resources, ESSA is also planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40862721/essa-pharma-presents-updated-phase-12-masofaniten-epi-7386-clinical-data-at-the-2024-esmo-congress" rel="noreferrer noopener">with other agents</a>.
As of&nbsp;September 30, 2024, the company had available cash reserves and short-term investments of&nbsp;$126.8 million&nbsp;and net working capital of&nbsp;$124.3 million.
In September, ESSA Pharma announced the presentation of updated dose escalation data from its Phase 1/2 study of masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 European Society for Medical Oncology (ESMO) Congress.
Across all dose cohorts, 88% of patients (14 of 16) achieved PSA50, 88% of patients (14 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 days, and 63% of patients (10 of 16) achieved PSA &lt;0.2ng/mL.
Price Action: EPIX stock was down 69.80% at $1.57 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Run: ai Acquisition Draws European Regulatory Scrutiny On Competition Concerns</a></li>
</ul>

Biotech

Health Care

Movers

EPIX

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) shares are trading lower after the company reported worse-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41679038/lyondellbasell-reports-third-quarter-2024-earnings" rel="noreferrer noopener">third-quarter results</a>.
LYB reported revenues of $10.332 billion, down 2.8% year over year and missing the consensus of $10.601 billion.
Adjusted EBITDA stood at $1.21 billion (-14.1% Y/Y), and the margin contracted by 154 bps to 11.7%. Adjusted EPS stood at $1.88, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">below the consensus of $1.98.</a>
North American polyethylene margins rose due to lower ethane and gas costs, with demand up over 7% year-to-date. High cracker operating rates boosted third-quarter&nbsp;ethylene volumes, while Europe and Asia margins benefited from lower feedstock costs.
LyondellBasell generated $670 million operating cash flow in the third quarter, with 80% cash conversion over 12 months.
The company invested $368 million in capital expenditures, returned $479 million to shareholders, and held $2.6 billion in cash with $7.3 billion in liquidity.
LyondellBasell&#8217;s CEO, Peter Vanacker, announced that the company started construction on its new MoReTec-1 facility in Germany, a key step toward a sustainable future.
Q4 Outlook: LyondellBasell anticipates softer demand in the fourth quarter due to seasonality, with sequentially higher natural gas and ethane feedstock&nbsp;costs likely impacting North American integrated&nbsp;polyolefins margins.
Operating rates are projected at 85% for North American O&amp;P assets, 60% for European O&amp;P, and 75% for I&amp;D assets, with easing interest rates expected to boost durable goods demand in 2025.
&#8220;Despite challenging global macroeconomic conditions, our strong North American operations allowed us to capitalize on favorable ethylene margins in the region,&#8221; said Vanacker.
Price Action: LYB shares traded lower by 0.98% at $86.00 premarket at the last check Friday.

Earnings

Equities

Guidance

LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4

Oppenheimer analyst Edward Yang maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Outperform and raises the price target from $260 to $275.

Price Target

Analyst Ratings

ONTO

Oppenheimer Maintains Outperform on Onto Innovation, Raises Price Target to $275

Oppenheimer analyst Jed Kelly maintains LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) with a Outperform and raises the price target from $65 to $70.

TREE

Oppenheimer Maintains Outperform on LendingTree, Raises Price Target to $70

Keybanc analyst Alex Markgraff maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and raises the price target from $515 to $580.

Keybanc Maintains Overweight on Mastercard, Raises Price Target to $580

Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $560 to $646.

ARGX

Oppenheimer Maintains Outperform on argenx, Raises Price Target to $646

Oppenheimer analyst Michael Phillips maintains Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Outperform and raises the price target from $165 to $177.

Oppenheimer Maintains Outperform on Hanover Insurance Gr, Raises Price Target to $177

JP Morgan analyst Doug Anmuth maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Neutral and lowers the price target from $60 to $58.

EBAY

JP Morgan Maintains Neutral on eBay, Lowers Price Target to $58

The U.S. Securities and Exchange Commission (SEC) announced Thursday that it has charged two affiliates of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) in five separate enforcement actions resulting in penalties and voluntary payments to investors of <a href="https://www.benzinga.com/markets/equities/24/10/41590849/jpmorgan-sues-customers-over-infinite-money-glitch-that-went-viral-on-tiktok-theyre-held-account">more than $151 million. </a>
The Details: The SEC<a href="https://www.sec.gov/newsroom/press-releases/2024-178"> charged</a> J.P. Morgan Securities LLC and J.P. Morgan Investment Management Inc. in five separate enforcement actions. Among the violations the agency flagged: misleading disclosures to investors, breach of fiduciary duty, prohibited joint transactions and principal trades, and failures to make recommendations in the best interest of customers. 
The JPMorgan affiliates agreed to pay more than $151 million in combined civil penalties and voluntary payments to investors to resolve the actions. The firm did not admit nor deny the findings in the SEC's orders. 
Read Next: <a href="https://www.benzinga.com/markets/asia/24/10/41656452/alibabas-strong-singles-day-sales-kickoff-hints-at-china-consumer-rebound">Alibaba&#8217;s Strong Singles&#8217; Day Sales Kickoff Hints At China Consumer Rebound</a>
"JPMorgan's conduct across multiple business lines violated various laws designed to protect investors from the risks of self-dealing and conflicts of interest," said Sanjay Wadhwa, Acting Director of the SEC's Division of Enforcement. 
"With today's settlements, which include multiple self-reports and large voluntary payments to harmed investors, JP Morgan is being held accountable for its regulatory failures," Wadhwa added.&nbsp;
One of the enforcement actions against J.P. Morgan Securities found that the firm made misleading disclosures to customers who invested in its Conduit private funds products which resulted in complaints from clients after the value of certain shares declined significantly.  
As part of the resolution, J.P. Morgan Securities agreed to make a voluntary payment of $90 million to more than 1,500 Conduit investor accounts. It also agreed to pay a civil penalty of $10 million, which will also be distributed to Conduit investors. 
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, JPMorgan shares are up 0.09 % at $222.13 at the time of publication Friday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41489239/bank-of-america-ceo-cautions-fed-not-to-go-too-fast-or-too-slow-on-interest-rate-cuts">Bank Of America CEO Cautions Fed Not To &#8216;Go Too Fast Or Too Slow&#8217; On Interest Rate Cuts</a></li>
</ul>
Image: Shutterstock&nbsp;

Large Cap

Legal

JPMorgan To Pay Investors $151 Million After SEC Flags 'Various Law Violations'

Oppenheimer analyst Ittai Kidron maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Outperform and raises the price target from $230 to $270.

TEAM

Oppenheimer Maintains Outperform on Atlassian, Raises Price Target to $270

JP Morgan analyst Tien-Tsin Huang maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and lowers the price target from $593 to $580.

JP Morgan Maintains Overweight on Mastercard, Lowers Price Target to $580

Keybanc analyst Justin Patterson maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and lowers the price target from $90 to $85.

UBER

Keybanc Maintains Overweight on Uber Technologies, Lowers Price Target to $85

Oppenheimer analyst Jason Helfstein maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and raises the price target from $220 to $230.

AMZN

Oppenheimer Maintains Outperform on Amazon.com, Raises Price Target to $230

<ul>
<li>AMZN</li>
<li>INTC</li>
<li>NVDA</li>
<li>AAPL</li>
<li>DJT</li>
<li>SMCI</li>
<li>LOT</li>
<li>AMD</li>
<li>MSFT</li>
<li>META</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

INTC

MSFT

NVDA

SMCI

Top 10 Trending Stocks On WallStreetBets As Of November 1, 2024 (Via Swaggy Stocks)

Morgan Stanley analyst Terence Flynn maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Equal-Weight and lowers the price target from $130 to $123.

Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $123

NRIM

Northrim BanCorp Acquires Sallyport Commercial Finance In All Cash Transaction Valued At $53.9M

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4292490-1&amp;h=325971108&amp;u=https%3A%2F%2Fwww.aon.com%2Fen%2F&amp;a=Aon+plc">Aon plc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), a leading global professional services firm, today announced the signing of a definitive agreement to acquire UK-based insurance broker Griffiths &amp; Armour. Upon completion of the transaction, Griffiths &amp; Armour will become wholly-owned by Aon UK Limited and is proposed to go to market as "Griffiths &amp; Armour, an Aon company".
The acquisition closely aligns with Aon's strategy to further expand its presence in the UK and Ireland. The combination will provide a greater breadth of solutions for clients across both Aon and Griffiths &amp; Armour with complementary strengths that create a platform for further growth in the UK, Ireland and beyond. Together, Aon and Griffiths &amp; Armour share a strong cultural alignment through an unwavering focus on clients and colleagues.

Aon To Acquire UK-Based Insurance Broker Griffiths & Armour; Financial Terms Not Disclosed

Morgan Stanley analyst Lauren Schenk maintains Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) with a Equal-Weight and raises the price target from $3.5 to $5.

PTON

Morgan Stanley Maintains Equal-Weight on Peloton Interactive, Raises Price Target to $5

Keybanc analyst Noah Zatzkin maintains Malibu Boats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>) with a Overweight and raises the price target from $38 to $50.

MBUU

Keybanc Maintains Overweight on Malibu Boats, Raises Price Target to $50

Tesla tops list of most heavily shorted securities in September, Hazeltree says

Bank of America Securities analyst Dimple Gosai maintained a Sell rating on Bloom Energy (BE – Research Report) on October 11 and set a price targe...

Bloom Energy: Sell Rating Justified by Market Challenges and Financial Uncertainty

In a report released today, Andrew Percoco from Morgan Stanley maintained a Buy rating on Bloom Energy (BE – Research Report), with a price target ...

Morgan Stanley Sticks to Its Buy Rating for Bloom Energy (BE)

Plug Power ($PLUG) is still in the throes of a difficult year, but one institutional investor isn't worried. Norges Bank, the Central Bank of Norwa...

Norway's Central Bank Boosts Stake in Plug Power (NASDAQ:PLUG)

Warning: BE is at high risk of performing badly

Truist Financial analyst Jordan Levy maintained a Hold rating on Bloom Energy (BE – Research Report) on October 17 and set a price target of $12.00...

Truist Financial Remains a Hold on Bloom Energy (BE)

There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Hexcel (HXL – Research Report) and Bloom Energ...

Analysts Offer Insights on Industrial Goods Companies: Hexcel (HXL) and Bloom Energy (BE)

Bullish option flow detected in Bloom Energy (BE) with 5,292 calls trading, 2x expected, and implied vol increasing over 1 point to 94.05%. 11/1 we...

Bloom Energy call volume above normal and directionally bullish

Piper Sandler analyst Kashy Harrison lowered the firm's price target on Bloom Energy (BE) to $10 from $11 on lower estimates, while keeping a Neutr...

Bloom Energy price target lowered to $10 from $11 at Piper Sandler

In a report released today, Kashy Harrison from Piper Sandler maintained a Hold rating on Bloom Energy (BE – Research Report), with a price target ...

Comments

Bloom Energy

Notizie

Ultime notizie per Bloom Energy (NYSE:BE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO